Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

320.24 -10.35 (-3.13%)
Streaming Delayed Price Updated: 3:16 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
Praxis Precision Medicines (NASDAQ:PRAX) Reports Q4 2025 Results Amid Key Regulatory Milestones ↗
Via Chartmill
Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position ↗
Via Stocktwits
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock ↗
Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of... 
Via Stocktwits
News headline image
Praxis Medicines Q4 2025 Earnings Call Transcript ↗
Praxis Medicines Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day. 
Via Stocktwits
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Why Praxis Precision Medicines Stock Popped Today ↗
A medical breakthrough is shining a light on the biotech's promising development platform. 
Via The Motley Fool
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗
Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor. 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗
The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies. 
Via Stocktwits
News headline image
What's going on in today's session ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗
The Data Monitoring Committee (DMC) recommended stopping the EMBOLD study ahead of schedule after the interim analysis demonstrated strong positive outcomes. 
Via Stocktwits
News headline image
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What&#39;s Going On? ↗
Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10— what's going on? 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards' ↗
Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the company's valuation. 
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Meet the Biotech Stock That Just Jumped 251% Higher ↗
Find out what sent this typically overlooked stock through the roof. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.